Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors

Anesthesiology. 2019 Nov;131(5):1153-1165. doi: 10.1097/ALN.0000000000002910.

Authors

Oliver Grottke¹, Sam Schulman

Affiliation

¹ From the Department of Anesthesiology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Germany (O.G.) Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, Canada (S.S.) Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Russia (S.S.).

PMID: 31415251
DOI: 10.1097/ALN.0000000000002910

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage
Anticoagulants / adverse effects*
Blood Coagulation Factors / pharmacology
Blood Coagulation Factors / therapeutic use*
Cohort Studies
Disease Management*
Factor X / antagonists & inhibitors*
Factor X / metabolism
Hemorrhage / chemically induced
Hemorrhage / metabolism
Humans

Substances

Anticoagulants
Blood Coagulation Factors
prothrombin complex concentrates
Factor X